How Growing Demand and Cost Pressures Are Reshaping the Biologics Discovery Landscape
The biologics discovery landscape is being reshaped by growing demand and cost pressures as biologics, including monoclonal antibodies, gene, RNA, and cell therapies, gain momentum with increasing FDA approvals, substantial market growth projected to exceed $700 billion by 2030, and strong investment flows, while innovators face the challenge of delivering novel, cost-effective treatments rapidly amid financial and development complexities.
Biologics have delivered much promise in treating cancer and rare diseases and they continue to gain ground in other wide-ranging areas, from neurological and metabolic disorders to respiratory and cardiovascular diseases. But along with the incredible potential biologics offer, there is also incredible pressure to deliver novel treatments both quickly and cost-effectively.
Growing Momentum of Biologics Research and Development
Biologics represent a rising share of FDA drug approvals, and their market size is projected to reach over $700 billion by 2030. According to The Antibody Society, over 150 therapeutic monoclonal antibodies have been approved for use in the US and Europe since first appearing more than two decades ago. While RNA therapies became mainstream with 2020’s mRNA-based COVID-19 vaccines, all areas of gene and cell therapy have been gaining momentum. The American Society of Gene and Cell Therapy (ASGCT) reports that, as of Q2 2022, 19 gene therapies, 18 RNA therapies, and 59 cell therapies have been approved for clinical use globally, with many promising candidates in trials.
Investment in biologics is strong, with ASGCT reporting that start-ups working in gene, cell, and RNA therapies raised nearly $800 million in Q2 of 2022 alone. A trend toward financing and alliances has emerged, letting investors and pharmaceutical companies support innovators without the full commitment of an acquisition.
Conflicting Financial Reality
Even as financing flows, innovators face a conflicting reality. On one side, there is incredible potential. Biologics offer several upsides, such as favorable safety, longer patents, and relatively low generic competition compared to small molecule drugs. There is also rising demand for novel treatments for prevalent chronic diseases, and biologics are poised to deliver thanks to research advances; recent examples include work researchers are doing to:
- Prevent the premature termination of protein expression caused by atypical stop codons resulting from genetic mutation
- Inhibit or alter protein expression by modifying RNA, such as with enzymes or small molecule drugs
- Uncover potential RNA target and drug candidates with the aid of artificial intelligence and machine learning
- Develop exosome delivery systems for gene therapy and RNA drugs
- Apply protein degraders to conditions outside oncology
- Perform gene editing with technology such as CRISPR
Unfortunately, the flipside to incredible potential is incredible pressure. Development costs for biologics are notoriously high. Patent cliffs are on the horizon. Federal policies have made biosimilar competition more viable. The call to lower drug prices and improve patient accessibility to novel biologic treatments is louder than ever. Innovators are left with no choice but to work smarter and faster, even from the earliest days of discovery. This is where Dotmatics can help.
Dotmatics Biologics Discovery Solutions
Dotmatics Biologics Discovery capabilities and expertise empower researchers to make the most of their data and accelerate programs across multiple modalities, including CAR-T, RNA, and antibody therapeutics.
The Dotmatics ecosystem includes trusted bioinformatics and molecular biology applications, including Geneious, SnapGene, Prism, and Protein Metrics, and provides an organized and harmonized structure needed to:
- Maximize efficiency and productivity
- Enable flexibility and easy access to shared data
- Accelerate discovery based on the quickly changing needs of the life science industry
To learn more about how Dotmatics can help address your team's specific challenges and make your data flow, talk to one of our experts today.
Related
The Rise of Biotech: Why Smaller Companies Are Outpacing Big Pharma on Innovation
Smaller biotech companies are increasingly outpacing big pharmaceutical firms in new molecular entity approvals due to their greater agility, willingness to take risks, and freedom to innovate despite funding challenges, with over half of upcoming blockbuster drug launches expected from first-time launchers who face higher risks but also potential for significant success.
Simplify your laboratory workflow management with Dotmatics
Dotmatics offers a unified scientific R&D platform that streamlines laboratory workflow management by integrating various scientific applications, automating data extraction, cleaning, and harmonization into FAIR formats, thereby reducing manual data handling, enhancing collaboration, and accelerating the R&D cycle to help life sciences organizations bring new therapies to market faster.
Our 11 Most-Read Blogs of 2023: AI, Biologics, ELNs, and More
Dotmatics' top blogs of 2023 highlight key scientific advancements including the convergence of small molecule and biologic drug development, the integration and comparison of LIMS and ELN systems for enhanced lab data management, and strategies to minimize human errors in biologics research through automation and calibration.
Four Moves Biotechs Can Make to Stay Competitive as Investor Confidence Shifts
As investor confidence in biotech has shifted from rapid, high-risk funding to more cautious, data-driven investment with longer timelines and stricter demands, biotechs must adapt by embracing innovative R&D platforms, demonstrating clear value through validated data and milestones, exploring flexible partnership models like co-development and joint ventures, and strategically managing growth to remain competitive in a market with tighter capital and evolving investor expectations.
Experience Collaborative Biologics Discovery
Dotmatics offers an end-to-end, data-driven software platform that digitizes and automates biologics R&D lab functions, enabling over 2 million researchers to rapidly access, visualize, and analyze complex biologics data—such as antibody, CAR-T, and RNA therapeutics—while integrating with familiar tools like GraphPad Prism and SnapGene to improve decision-making and accelerate drug discovery.
Dotmatics Launches BioGlyph Luma to Accelerate the Future of Protein Design & Engineering
Dotmatics has launched BioGlyph Luma, a next-generation protein design and engineering solution integrated into its Luma Scientific Intelligence Platform, which addresses the Design phase of the protein therapeutics research cycle by enabling real-time traceability, scalable registration, and seamless integration with existing scientific tools to accelerate multimodal biologic R&D workflows with precision and data-driven automation.